Hengrui Pharma presents 64 studies at ESMO 2026, a record for the Chinese oncology company showcasing 14 approved innovative ...
Qutenza meets primary pain endpoint in post-surgical neuropathy trial, showing sustained benefit over ten months in extension ...
Atrium Therapeutics doses first patient in ATR-1072 trial for PRKAG2 syndrome, targeting the genetic cause of cardiac disease ...
Enanta dosed its first RESOLVE patient Oct 26. High-risk adult RSV outpatient capacity is already strained, here's what site ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results